RBM22P12

Across TCGA pan-cancer cohorts, RBM22P12 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RBM22P12 data layer.

The strongest signal is observed in kidney chromophobe (KICH), where higher RBM22P12 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM22P12 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

KICH, MESO, and PCPG are the cancer types where RBM22P12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Tertile	All	0.081	0.904	<.001	90	view →
MESO	OS	Tertile	All	0.130	0.557	.019	54	view →
PCPG	DFS	Tertile	All	0.215	0.809	<.001	24	view →
LAML	DFS	Tertile	All	0.379	0.614	.024	18	view →
UCEC	DFS	Tertile	III,IV	0.103	0.587	.049	18	view →
LIHC	OS	Tertile	III,IV	0.266	0.652	.043	9	view →
CESC	DFS	Tertile	All	0.709	0.826	.047	6	view →
STAD	OS	Quartile	All	0.308	0.572	.034	4	view →
LUSC	DFS	Tertile	All	0.861	0.735	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RBM22P12–KICH (DFS)

Open the KICH breakdown →